Moderna's mRNA RSV vaccine wins expanded FDA approval for younger adults

Moderna's mRNA RSV vaccine wins expanded FDA approval for younger adults
The FDA has expanded approval for Moderna's RSV vaccine to include younger adults at risk, pending national immunization schedule recommendations. mRESVIA is the first non-Covid-19 mRNA vaccine in the US, now available for ages 18-59 alongside 60+.